Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Huntington disease | D006816 | Orphanet_399 | G10 | 1 | 4 | 2 | — | — | 7 |
Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | — | 2 | 2 | — | 1 | 3 |
Motor neuron disease | D016472 | EFO_0003782 | G12.2 | — | 2 | 2 | — | 1 | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
Dyskinesias | D020820 | HP_0002310 | G24 | — | 1 | — | — | — | 1 |
Drug common name | Pridopidine |
INN | pridopidine |
Description | Pridopidine (also known as PL-101) is an orally administrated small molecule investigational drug. Pridopidine is a selective and potent Sigma-1 Receptor agonist. It is being developed by Prilenia Therapeutics and is currently in late-stage clinical development for Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
|
Classification | Small molecule |
Drug class | dopamine D2 receptor modulator |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCCN1CCC(c2cccc(S(C)(=O)=O)c2)CC1 |
PDB | — |
CAS-ID | 346688-38-8 |
RxCUI | — |
ChEMBL ID | CHEMBL596802 |
ChEBI ID | — |
PubChem CID | 9795739 |
DrugBank | DB11947 |
UNII ID | HD4TW8S2VK (ChemIDplus, GSRS) |